Product Description
Allopurinol is used to treat gout, high levels of uric acid in the body caused by certain cancer medications, and kidney stones. Allopurinol is in a class of medications called xanthine oxidase inhibitors. It works by reducing the production of uric acid in the body. High levels of uric acid may cause gout attacks or kidney stones. Allopurinol is used to prevent gout attacks, not to treat them once they occur. (Sourced from: https://medlineplus.gov/druginfo/meds/a682673.html)
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, Estonia, Finland, Germany, Italy, Netherlands, Norway, Poland, Portugal, Spain, Switzerland, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Brain Injuries|Congenital Heart Defects|Gout|Hypoxia-Ischemia, Brain
Phase 2: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04217421 |
CRUCIAL | P3 |
Recruiting |
Congenital Heart Defects |
2026-10-31 |
2024-05-17 |
Primary Endpoints |
|
NCT05665699 |
D0120-205 | P2 |
Active, not recruiting |
Gout |
2025-07-31 |
50% |
2025-05-09 |
Primary Endpoints|Treatments|Trial Status |
2022-503063-15-00 |
CARTemis-1 | P2 |
Not yet recruiting |
Multiple Myeloma |
2030-03-31 |
2025-05-02 |
Treatments |
|
NCT03162653 |
ALBINO | P3 |
Recruiting |
Hypoxia-Ischemia, Brain|Brain Injuries |
2026-01-31 |
2023-07-12 |
Primary Completion Date|Primary Endpoints |
|
NCT04956432 |
SHR4640-303 | P3 |
Completed |
Gout |
2023-12-13 |
24% |
2025-01-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06056570 |
UR1-DOT-103 | P2 |
Completed |
Gout |
2024-06-27 |
2025-01-30 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05586971 |
EURELIA2 | P3 |
Completed |
Gout |
2025-05-06 |
31% |
2025-05-16 |
Primary Completion Date|Primary Endpoints |